Skip to content
Clinical Trials – home

Alergologia Plus Sp. z o.o.

Verified siteinfo

Poland Ul. Tomasza Drobnika 49, 60-693 Poznan, Poland

  • 14 trials recruiting
  • Asthma · Chronic obstructive pulmonary disease · Chronic spontaneous urticaria
  • Adults and children

About Specializations

Alergologia Plus Sp. z o.o. in Poznan, Poland specialises in clinical trials of conditions such as Asthma, Chronic obstructive pulmonary disease, Chronic spontaneous urticaria, Chronic rhinosinusitis with nasal polyps, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases and Allergic Conditions

At Alergologia Plus Sp. z o.o. in Poznan, research in immune system diseases focuses on conditions such as atopic dermatitis, chronic spontaneous urticaria, and birch pollen-induced allergic rhinoconjunctivitis. These studies are designed to test new treatment options and compare them with existing therapies, with the goal of improving symptom control and long-term disease management.

  • Testing new therapies for atopic dermatitis in children and adults
  • Evaluating treatment options for chronic spontaneous urticaria
  • Assessing relief strategies for allergic rhinoconjunctivitis caused by birch pollen

This area reflects a strong interest in better controlling allergic and inflammatory skin disorders while improving day-to-day comfort for patients.

Respiratory Tract Diseases

A major part of the research portfolio at Alergologia Plus Sp. z o.o. centers on respiratory tract diseases, especially asthma and chronic obstructive pulmonary disease. The trials are aimed at evaluating how well new and existing treatments reduce symptoms, improve lung function, and lower the risk of flare-ups in people with persistent breathing problems.

  • Studying therapies for moderate-to-severe asthma and severe eosinophilic asthma
  • Assessing treatment effectiveness in chronic obstructive pulmonary disease
  • Exploring ways to reduce asthma exacerbations and improve lung function

The site contributes to research that aims to make breathing easier and reduce the burden of chronic airway inflammation.

Otorhinolaryngologic Diseases

Clinical studies in otorhinolaryngologic diseases at this research site focus on chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. The main purpose is to evaluate therapies that may reduce nasal blockage, improve sinus symptoms, and lessen the impact of ongoing inflammation in the nose and sinuses.

  • Research on chronic rhinosinusitis with nasal polyps
  • Trials for chronic rhinosinusitis without nasal polyps
  • Assessing treatments to improve nasal congestion and sinus-related symptoms

These studies support better care for patients living with long-lasting sinus disease and related breathing discomfort.

Skin and Connective Tissue Diseases

Research in skin and connective tissue diseases includes work on atopic dermatitis, a condition marked by chronic inflammation, itching, and skin irritation. The trials are focused on comparing therapies and improving disease control, especially for patients who need systemic treatment options.

  • Evaluating new approaches for atopic dermatitis
  • Comparing therapies to improve symptom relief and patient outcomes
  • Supporting studies of inflammatory skin disease management

This research area highlights the site’s interest in advancing treatment choices for chronic skin inflammation and related quality-of-life concerns.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Tomasza Drobnika 4960-693 PoznanPoland
Recruiting now
14 trials
Conditions studied
10
Partner status
Verified site

More sites in PoznanPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

44 clinical trials

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthma

Recruiting

A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD6793
  • Sponsor:AstraZeneca AB

Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Asthma

Recruiting

A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

A study to evaluate the efficacy and safety of lesigercept in adults with chronic spontaneous urticaria who do not have enough relief from antihistamines

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Yuhan Corp.

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.